PRIMARY STUDY
Role of cannabis in inflammatory bowel diseases
Key Findings: This review of the endocannabinoid system (ECS) and its role in inflammatory conditions of the gastrointestinal (GI) tract finds that when the ECS is activated it reduces gut motility, secretions, cellular permeability, and causes inflammatory and immune cascades. This mechanism is believed to be through the ECS receptors of the enteric nervous and immune systems. However, medicinal cannabis use in the treatment of inflammatory bowel disease (IBD) is not yet confirmed as the quality of available studies is questionable.
Type of Study: Meta-analysis
Study Result: Inconclusive
Study Location(s): United States
Year of Pub: 2022
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), AM-x Synthetic Cannabinoids, JWH-x Synthetic Cannabinoids, Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Synthetic Cannabinoid (unspecified), Endocannabinoid (unspecified), Pharma THC, Pharma THC:CBD
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2, GPCR 55, TRPV1
Ligands Studied: Dopamine, Glutamate, Pro-inflammatory cytokines
DOSING DETAILS 
Study Dosing Objective: Effective Dose
Established Protocol: No effective dose
Route of Administration: Inhalation, Oral (Ingestion)
Cannabinoid Ratio: (CBD : THC) 0 : 0 
Dosing Regimen: Crohn's Disease: 115 mg THC or 10 mg CBD twice a day Ulcerative Colitis: 50 - 250 mg of CBD or 23 mg THC per day
Clinical Relevance: Cannabis for medicinal use in irritable bowel disease (IBD) is still questionable
Link to study
